截至发稿，胡洁累计任职时间13年89天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 178.56%， 任职期间最差基金回报-98.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，华宝基金旗下1只基金位居华大基因十大流通股东。华宝中证医疗ETF（512170）三季度减 持120.88万股，持有股数710.98万股，占流通股的比例为1.71%。根据测算，今日浮盈赚取约1855.67万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益7.81%，同类 排名536/5509；近一年收益18.34%，同类排名3411/4198；成立以来收益9.75%。 华宝中证医疗ETF（512170）基金经理为胡洁。 1月9日，华大基因涨5.43%，截至发稿，报50.65元/股，成交3.64亿元，换手率1.76%，总市值211.88亿 元。 资料显示，深圳华大基因股份有限公司位于广东 ...

从三诺生物十大流通股东角度 数据显示，华宝基金旗下1只基金位居三诺生物十大流通股东。华宝中证医疗ETF（512170）三季度减 持150.68万股，持有股数961.42万股，占流通股的比例为2.13%。根据测算，今日浮盈赚取约894.12万 元。 1月9日，三诺生物涨5.21%，截至发稿，报18.77元/股，成交1.79亿元，换手率2.15%，总市值105.16亿 元。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路265号，成立日期 2002年8月7日，上市日期2012年3月19日，公司主营业务涉及以生物传感技术为基础的相关慢性疾病即 时检测(POCT)产品的研发、设计、生产和销售。主营业务收入构成为：血糖监测系统73.29%，糖尿病 营养、护理等辅助产品6.59%，糖化血红蛋白检测系统5.03%，血脂检测系统4.14%，血压计4.11%， iPOCT监测系统3.94%，经营品2.05%，其他0.85%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年89天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 178.56%， 任职期间 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 1月5日，万东医疗涨5.39%，截至发稿，报16.42元/股，成交1.53亿元，换手率1.35%，总市值115.44亿 元。 资料显示，北京万东医疗科技股份有限公司位于北京市朝阳区酒仙桥东路9号院3号楼，成立日期1997年 5月12日，上市日期1997年5月19日，公司主营业务涉及从事影像类医疗器械的研发、制造、销售及影像 诊断服务。主营业务收入构成为：医疗器械销售业务90.72%，医疗服务及其他5.66%，其他(补 充)3.62%。 从万东医疗十大流通股东角度 数据显示，华宝基金旗下1只基金位居万东医疗十大流通股东。华宝中证医疗ETF（512170）三季度减 持209.86万股，持有股数1191.98万股，占流通股的比例为1.7%。根据测算，今日浮盈赚取约1001.26万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益3.89%，同类 排名3822/4189；近一年收益3.89%，同类排名3822/4189；成立以来收益1.8%。 截至发稿，胡洁累计任职时间13年85天，现任基金资产总规模1002 ...

Core Viewpoint - Sanofi Bio's stock decreased by 1.04% to 17.13 CNY per share, with a total market capitalization of 9.597 billion CNY as of the report date [1] Group 1: Company Overview - Sanofi Bio was established on August 7, 2002, and went public on March 19, 2012 [1] - The company specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic disease detection [1] - The revenue composition of Sanofi Bio includes: 73.29% from blood glucose monitoring systems, 6.59% from diabetes nutrition and care products, 5.03% from glycated hemoglobin testing systems, 4.14% from blood lipid testing systems, 4.11% from blood pressure monitors, 3.94% from iPOCT monitoring systems, 2.05% from other products, and 0.85% from miscellaneous [1] Group 2: Shareholder Information - Huabao Fund's Huabao CSI Medical ETF (512170) is among the top ten circulating shareholders of Sanofi Bio, having reduced its holdings by 1.5068 million shares in the third quarter, now holding 9.6142 million shares, which is 2.13% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.7306 million CNY [2] - The fund was established on May 20, 2019, with a current size of 26.404 billion CNY, yielding 5.42% this year, ranking 3760 out of 4195 in its category [2]

12月25日，美好医疗涨5.15%，截至发稿，报23.87元/股，成交2.59亿元，换手率2.95%，总市值135.79 亿元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益5.39%，同类 排名3758/4197；近一年收益1.8%，同类排名3881/4170；成立以来收益3.27%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年74天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 177.89%， 任职期间最差基金回报-98.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，深圳市美好创亿医疗科技股份有限公司位于广东省深圳市龙岗区宝龙街道宝龙六路3号新中 桥工业园B栋2楼，成立日期2010年7月15日，上市日期2022年10月12日，公司主营业务涉及医疗器械精 密组件及产品的设计开发、制造和销售。主营业务收入构成为：家用呼 ...

（来源：数据GO） 前期介绍了一些非常优秀的基金，它们赚了不少钱，看起来投资似乎是手拿把掐的事。 其实，风险与收益并存，也有一些基金因为系统性原因或布局失误亏了很多钱，比如市场上现有股票型基金亏损超100亿元的就有4只，而且这4只基金均 为指数基金。 作为医疗行业的代表性ETF，该基金跟踪中证医疗指数。2020年至2021年上半年，受疫情等因素推动，医疗板块涨幅显著，估值处于历史高位。但随着集 采政策深化、行业增速放缓，板块整体进入调整期，叠加2022年以来市场整体走弱，该基金净值持续承压，累计亏损超过140亿元。这体现了行业指数基 金在行业周期与政策环境变化下面临的显著风险。 3.招商国证生物医药A：创新药行业波动与资本退潮 成立或规模扩张于板块热度较高时期，资金集中流入推动规模上升，但也埋下了估值过高、回调压力大的隐患。 所跟踪的行业或主题板块具有高波动、强周期或强政策敏感性，在行业景气度下行或估值消化阶段，指数基金无法通过主动调仓规避风险。 1.富国国企改革A：政策预期与市场周期的双重考验 该基金成立于2014年，跟踪中证国有企业改革指数。2015年上半年，国企改革主题在政策预期与牛市情绪推动下受到市场 ...

Group 1 - The core point of the news is that Aihuilong's stock price increased by 5.21% to 16.15 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.77%, resulting in a total market capitalization of 9.212 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay methods [1] - The company's revenue composition includes self-produced reagents (non-COVID products) at 58.57%, self-produced consumables (non-COVID products) at 12.60%, self-produced instruments (non-COVID products) at 11.92%, and various agency sales [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund holds a significant position, having reduced its holdings by 1.7669 million shares in the third quarter, now owning 9.6516 million shares, which is 1.69% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) has a total scale of 26.404 billion CNY and has achieved a year-to-date return of 11.75% [2] - The fund manager, Hu Jie, has a tenure of 13 years and 31 days, with the fund's total asset scale reaching 100.204 billion CNY [3]

Group 1 - The core point of the article is that Yingke Medical's stock price increased by 5.3% to 40.74 CNY per share, with a trading volume of 445 million CNY and a turnover rate of 2.39%, resulting in a total market capitalization of 26.676 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] - The top circulating shareholder of Yingke Medical is Huabao Fund, which reduced its holdings in the Huabao Zhongzheng Medical ETF by 2.2149 million shares, now holding 12.8002 million shares, representing 2.75% of circulating shares [2] Group 2 - The Huabao Zhongzheng Medical ETF, managed by Hu Jie, has a total asset size of 100.204 billion CNY, with a best fund return of 182.37% and a worst return of -98.01% during Hu Jie's tenure [3] - The Huabao Zhongzheng Medical ETF was established on May 20, 2019, with a latest scale of 26.404 billion CNY, achieving a year-to-date return of 10.25% and a one-year loss of 1.07% [2]

Core Viewpoint - As of November 4, the total margin balance for ETFs in the Shanghai and Shenzhen markets is 121.307 billion yuan, showing a decrease of 0.347 billion yuan from the previous trading day [1] Group 1: ETF Financing and Margin Data - The ETF financing balance is 113.006 billion yuan, down by 0.521 billion yuan compared to the previous trading day [1] - The ETF margin short balance is 8.301 billion yuan, which increased by 0.174 billion yuan from the previous trading day [1] Group 2: Net Buy Data - On November 4, 291 ETFs experienced net financing purchases, with the Huatai-PB Hang Seng Technology ETF leading with a net purchase amount of 83.7145 million yuan [1] - Other ETFs with significant net purchase amounts include the Huaxia Hang Seng Technology ETF, Huaxia CSI Robotics ETF, Huitianfu CSI Major Consumption ETF, Huabao CSI Medical ETF, and Huaxia Hang Seng Internet Technology ETF [1]

Core Points - On October 30, Xinmai Medical experienced a decline of 5.03%, trading at 100.12 CNY per share, with a transaction volume of 375 million CNY and a turnover rate of 3.00%, resulting in a total market capitalization of 12.341 billion CNY [1] Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. was established on August 17, 2012, and went public on July 22, 2019. The company specializes in the research, development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1] - The revenue composition of the company is as follows: 71.94% from aortic products, 28.04% from peripheral and other products, and 0.02% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xinmai Medical, a fund under Huabao Fund holds a significant position. The Huabao CSI Medical ETF (512170) reduced its holdings by 301,200 shares in the third quarter, now holding 2.115 million shares, which accounts for 1.72% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 26.404 billion CNY. Year-to-date, it has achieved a return of 15%, ranking 3359 out of 4216 in its category; over the past year, it has returned 8.02%, ranking 3532 out of 3885; and since inception, it has returned 12.69% [2] - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a tenure of 13 years and 18 days, managing total assets of 100.204 billion CNY. During his tenure, the best fund return was 180.89%, while the worst was -98.01% [2]